Literature DB >> 29967835

Factors Favouring the Development of Clostridium Difficile Infection in Critically Ill Patients.

Bianca-Liana Grigorescu1, Raluca Ştefania Fodor1, Adrian Dan Cioc2, Mihaly Veres2, Monica Orlandea2, Bogdan Lăzescu2, Emoke Almasy2.   

Abstract

Clostridium difficile, an anaerobic, spore-forming, toxin-forming, gram-positive bacillus present in the bacterial flora of the colon is the principal cause of nosocomial diarrhoea in adults. AIM: Assessment of favouring factors of Clostridium difficile infections as well as the interactions between them, in critically ill hospitalized patients undergoing complex medical and surgical treatments.
MATERIAL AND METHODS: A retrospective case-control study involving eighty patients admitted in the Intensive Care Unit (ICU) of the County Clinical Emergency Hospital Tîrgu-Mureş was conducted between January and October 2014. Patients aged eighteen years and over, who had undergone complex medical and surgical treatment, were divided into two subgroups. Group 1 included patients who developed diarrhoea but were not diagnosed as having a Clostridium difficile infection (CDI). Group 2 included patients who developed diarrhoea due to CDI as indicated by a positive culture and the expression of exotoxin. The assessed parameters were age, length of stay (LOS), antibiotic spectrum, association with proton pump inhibitors (PPI) or H2-receptor antagonists, immunological status, the presence or lack of gastrointestinal tract surgery.
RESULTS: The mean age was 64.6 years with an average LOS of 10 days. Fifty-six percent of patients came to the ICU from internal medicine wards and forty-three percent from surgical wards. 20.5% of them were immunosuppressed. Co-association of ceftriaxone and pantoprazole significantly increased the risk of CDI compared to co-administration of any other antibiotic or pantoprazole (p=0.01). The odds ratio for Pantoprazole together with any antibiotic versus antibiotic therapy alone was significantly higher (p=0.018) with a sevenfold increase in the risk of positive exotoxin increase.
CONCLUSIONS: Antibiotic use is associated with "no risk to develop CDI" in the first five days of administration. PPIs associated therapy increased the risk of CDI in first seventy-two hours regardless of the antibiotic type, and contributes to an active expression of CD exotoxin.

Entities:  

Keywords:  Clostridium difficile; Pantoprazole; antibiotic therapy; nosocomial infection

Year:  2016        PMID: 29967835      PMCID: PMC5939141          DOI: 10.1515/jccm-2016-0006

Source DB:  PubMed          Journal:  J Crit Care Med (Targu Mures)        ISSN: 2393-1817


  21 in total

Review 1.  The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens.

Authors:  Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2004-06-25       Impact factor: 9.079

2.  Proton pump inhibitors and risk for recurrent Clostridium difficile infection.

Authors:  Amy Linsky; Kalpana Gupta; Elizabeth V Lawler; Jennifer R Fonda; John A Hermos
Journal:  Arch Intern Med       Date:  2010-05-10

3.  Gastrin-mediated effects of omeprazole on rat colon mucosa.

Authors:  M E Klingensmith; L J Neville; E Delpire; M M Wolfe; D I Soybel
Journal:  Surgery       Date:  1999-08       Impact factor: 3.982

4.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

Review 5.  Clostridium difficile infection: clinical challenges and management strategies.

Authors:  Pamela R Walters; Brian S Zuckerbraun
Journal:  Crit Care Nurse       Date:  2014-08       Impact factor: 1.708

6.  Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study.

Authors:  K R Neal; H M Scott; R C Slack; R F Logan
Journal:  BMJ       Date:  1996-02-17

7.  Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals.

Authors:  Becky A Miller; Luke F Chen; Daniel J Sexton; Deverick J Anderson
Journal:  Infect Control Hosp Epidemiol       Date:  2011-04       Impact factor: 3.254

8.  Clostridium difficile--associated disease in a setting of endemicity: identification of novel risk factors.

Authors:  Erik R Dubberke; Kimberly A Reske; Yan Yan; Margaret A Olsen; L Clifford McDonald; Victoria J Fraser
Journal:  Clin Infect Dis       Date:  2007-12-15       Impact factor: 9.079

9.  Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit.

Authors:  Robert MacLaren; Paul M Reynolds; Richard R Allen
Journal:  JAMA Intern Med       Date:  2014-04       Impact factor: 21.873

10.  Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients.

Authors:  Jeffrey F Barletta; David A Sclar
Journal:  Crit Care       Date:  2014-12-24       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.